Journal of diabetes and its complications最新文献

{"title":"The prognostic value of the stress hyperglycemia ratio for all-cause mortality in stroke patients with diabetes or prediabetes","authors":"Meng Jin ,&nbsp;Ziyi Bao ,&nbsp;Xiaqing Hong ,&nbsp;Songbin He ,&nbsp;Feng Gao","doi":"10.1016/j.jdiacomp.2025.108979","DOIUrl":"10.1016/j.jdiacomp.2025.108979","url":null,"abstract":"<div><h3>Background</h3><div>The stress hyperglycemia ratio (SHR), originally proposed in 2015 by Robert et al., is more significantly relevant and predictive of critical illness than absolute hyperglycemia. Several studies have validated the association between stress hyperglycemia ratio and cerebrovascular disease. However, the value of stress hyperglycemia ratio for severe stroke patients admitted to the ICU remains uncertain. The aim of this study was to investigate the relationship between stress hyperglycemia ratio and clinical short- and long-term prognosis of critically ill patients with acute ischemic stroke (AIS).</div></div><div><h3>Methods</h3><div>Clinical data from 893 critically ill patients with ischemic stroke (IS) were extracted from the Medical Information Marketplace for Intensive Care (MIMIC-IV) database and 793 critically ill IS patients with 1 year of follow-up. The SHR is expressed by the formula: SHR = [(admission glucose (mg/dl)) / (28.7 × HbA1c (%) − 46.7)]. The study population was categorized into quartiles based on SHR level. Outcomes included ICU mortality, hospital mortality, and 1-year mortality. Cox proportional risk regression analysis and restricted cubic spline curves were used to elucidate the association between SHR and clinical prognosis in critically ill patients with AIS.</div></div><div><h3>Results</h3><div>There were 69 ICU deaths and 100 in-hospital deaths in cohort 1, and 229 patients experienced all-cause mortality during the 1-year follow-up in cohort 2. Multivariate Cox proportional risk analysis showed that elevated SHR was significantly associated with an increased risk of hospital and 1-year all-cause mortality. After adjusting for confounders, patients with elevated SHR were significantly associated with hospital mortality (adjusted risk ratio, 1.870; 95 % confidence interval, 1.180–2.962; <em>P</em> = 0.008) and 1-year mortality (adjusted risk ratio, 2.325; 95 % confidence, 1.729–3.127; <em>P</em> &lt; 0.001). Restricted cubic spline bars showed that a progressively increasing risk of all-cause mortality was associated with an elevated SHR.</div></div><div><h3>Conclusion</h3><div>Stress hyperglycemia ratios were significantly associated with in-hospital and 1-year all-cause mortality in critically ill IS patients. Moreover, we found that non-diabetic and prediabetic patients showed an increased risk of all-cause mortality. It is suggested that SHR may be useful in identifying ischemic stroke patients at high risk of all-cause mortality and providing personalized interventions as early as possible.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108979"},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating social determinants of health into global approaches to early-onset type 2 diabetes","authors":"J. Eleanor Seo ,&nbsp;Manfredi Rizzo ,&nbsp;Tiffany M. Powell-Wiley","doi":"10.1016/j.jdiacomp.2025.108982","DOIUrl":"10.1016/j.jdiacomp.2025.108982","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108982"},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis","authors":"Lingyan Liu ,&nbsp;Yongkun Deng ,&nbsp;Lijuan Yang ,&nbsp;Miaojiao Wang ,&nbsp;Yong Lai","doi":"10.1016/j.jdiacomp.2025.108998","DOIUrl":"10.1016/j.jdiacomp.2025.108998","url":null,"abstract":"<div><h3>Objective</h3><div>To comprehensively evaluate the therapeutic efficacy of pioglitazone and SGLT2 inhibitors (SGLT2i) in patients with MASLD and Type 2 Diabetes(T2DM).</div></div><div><h3>Methods</h3><div>Electronic databases, including Web of Science, PubMed, the Cochrane Library, China National Knowledge Internet (CNKI), Wan-Fang Digital Database, and China Science and Technology Journal Database (VIP) were searched from inception to December 2024. Two reviewers independently assessed study eligibility, performed continuous data extraction， and independently evaluated bias risks. Liver ultrasonography, computed tomography (CT), and biochemical indices were utilized to determine the impact of treatment in both groups. Improvement in liver biomarkers and fibrosis as primary outcome indicators; Improvement in body composition, metabolic parameters, glucose parameters, and incidence of adverse effects as a secondary outcome indicator. For continuous variables, mean and standard deviation (SD) were extracted. RevMan 5.4 software was used to systematically analyze the literature, including heterogeneity testing, odds ratios (OR) calculation, and 95 % confidence intervals (CI) for each influencing factor.</div></div><div><h3>Results</h3><div>Nine randomly controlled trials with 755 Asian participants were included. Our research showed that SGLT2i was more effective than pioglitazone in improving fibrosis-4 score (SMD 0.41 [95%CI 0.18,0.64] <em>p</em> = 0.005), visceral fat area (SMD 0.34 [95%CI 0.14,0.54] <em>p</em> = 0.0007), BMI (SMD 0.29 [95%CI 0.03,0.56] <em>p</em> = 0.03), and low-density lipoprotein levels (SMD 0.21 [95%CI 0.04,0.38] <em>p</em> = 0.01). In contrast, no statistically significant differences were observed in other outcomes.</div></div><div><h3>Conclusions</h3><div>Our study demonstrated that in patients with MASLD and T2DM, SGLT2i was more effective overall in improving liver fibrosis, blood lipids, liver fat, and body composition in the short term. These findings establish a theoretical basis for safe and rational drug use in clinical practice. Additionally, they may contribute to new insights into the pathogenesis of MASLD and type 2 diabetes and drug discovery and development efforts.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108998"},"PeriodicalIF":2.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"sCD14 as a biomarker for the progression of kidney disease among patients with diabetes","authors":"Oscar Zaragoza-García ,&nbsp;Olivia Briceño ,&nbsp;José Rafael Villafan-Bernal ,&nbsp;Héctor Ugo Rojas-Delgado ,&nbsp;Ilse Adriana Gutiérrez-Pérez ,&nbsp;Cristina Morales-Martínez ,&nbsp;Roma Rubí Rodriguez-Reyes ,&nbsp;Iris Paola Guzmán-Guzmán","doi":"10.1016/j.jdiacomp.2025.108980","DOIUrl":"10.1016/j.jdiacomp.2025.108980","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the association of soluble CD14 (sCD14) with diabetic kidney disease (DKD) and its prediction performance for kidney function staging.</div></div><div><h3>Methods</h3><div>A cross-sectional study of 80 type 2 diabetes (T2D) patients was conducted. Each participant was screened for DKD, and the diagnostic criterion for DKD was a glomerular filtration rate (eGFR) &lt;60 mL/min/1.73m². Serum sCD14 was measured by ELISA technique. Logistic regression models and receiver operating characteristics (ROC) curves were used to assess the association of sCD14 with DKD and its predictive value for disease staging.</div></div><div><h3>Results</h3><div>sCD14 was higher in DKD patients than in T2D patients without kidney disease (<em>p</em> &lt; 0.001). sCD14 was progressively higher in DKD patients according to the kidney function stage (<em>p</em> &lt; 0.001). Also, sCD14 was higher in DKD patients in hemodialysis than those who did not receive renal replacement therapy (<em>p</em> &lt; 0.001). In DKD patients, sCD14 was positively correlated with creatinine (<em>r</em> = 0.282, <em>p</em> = 0.042) and negatively correlated with eGFR (<em>r</em> = −0.365, <em>p</em> = 0.007). The levels of sCD14 were predictive of G3 (AUC = 0.822), G4 (AUC = 0.876), and G5 (AUC = 0.924) stages of kidney function. In a multivariate logistic regression model adjusted for age, sex, and diabetes duration, sCD14 ≥ 1720 ng/mL were associated with G3 stage (OR = 8.92, <em>p</em> = 0.023), G4 (OR = 7.92, <em>p</em> = 0.011) and G5 stage (OR = 18.47, <em>p</em> = 0.017) in DKD patients.</div></div><div><h3>Conclusion</h3><div>Circulating levels of sCD14 are associated with DKD and perform well for kidney function staging. Thus, it is a good candidate for assessing the risk of kidney disease progression.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108980"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of automated insulin delivery (AID) systems on quality of life (QoL): Validation of the AID-QoL questionnaire","authors":"Giuseppe Papa ,&nbsp;Rossella Cannarella ,&nbsp;Concetta Finocchiaro ,&nbsp;Massimiliano Anzaldi ,&nbsp;Gianfranco Gruttadauria ,&nbsp;Donatella Lo Presti ,&nbsp;Rosita A. Condorelli ,&nbsp;Sandro La Vignera ,&nbsp;Aldo E. Calogero","doi":"10.1016/j.jdiacomp.2025.108984","DOIUrl":"10.1016/j.jdiacomp.2025.108984","url":null,"abstract":"<div><h3>Background and aim</h3><div>Evidence supports the efficacy of automated insulin delivery (AID) systems in improving glycometabolic outcomes. However, limited data are available on their impact on quality of life (QoL). This study aimed to develop and validate a questionnaire to assess QoL in subjects with type 1 diabetes mellitus (T1DM) using AID system (AID-QoL).</div></div><div><h3>Patients and methods</h3><div>A questionnaire was developed and validated following a standardized procedure and administered to 219 subjects with T1DM who were using AID systems for insulin therapy.</div></div><div><h3>Results</h3><div>Analysis of inter-expert agreement for internal consistency showed a Cronbach's alpha coefficient of 0.720, suggesting an acceptable level of consistency across the 29 items of the AID-QoL. The infraclass correlation coefficient for retest agreement was 0.745, demonstrating “substantial” reliability. Administration of the questionnaire to the 219 subjects with T1DM showed that AID systems contributed to high satisfaction with glycometabolic management, a slightly lower satisfaction with the technical aspects of the AID systems, a positive impact on psychological and social well-being, and a high level of confidence in the technology.</div></div><div><h3>Conclusion</h3><div>The AID-QOL questionnaire is a newly validated, reliable, easy-to-use tool for measuring QoL and satisfaction in subjects with T1DM who are receiving insulin treatment via AID systems.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108984"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline-directed medical therapies (GDMTs) for chronic kidney disease with type 2 diabetes (CKD + T2D): Translation of lessons learned from the management of heart failure","authors":"Jonathan Rollins ,&nbsp;Alison L. Hong ,&nbsp;Bridgette Schroader ,&nbsp;Sheldon X. Kong ,&nbsp;Barb Lennert ,&nbsp;Jennifer Cameron ,&nbsp;Rakesh Singh ,&nbsp;Yuxian Du ,&nbsp;Todd Williamson","doi":"10.1016/j.jdiacomp.2025.108985","DOIUrl":"10.1016/j.jdiacomp.2025.108985","url":null,"abstract":"<div><div>Although guideline-directed medical therapy (GDMT) is an evidence-based, proven approach to manage chronic kidney disease and type 2 diabetes (CKD + T2DM), adherence is low and multifactorial. Opportunities exist to improve care delivery, thus delaying disease progression, avoiding unnecessary costs, and potentially improving quality of life for patients both diagnosed and yet to be diagnosed.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108985"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00043-1","DOIUrl":"10.1016/S1056-8727(25)00043-1","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108990"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143528872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of adding glucagon-like peptide-1 receptor agonist on diabetes complications and mortality among basal insulin-treated people with type 2 diabetes: A real-world Korean study","authors":"Kyoung Hwa Ha ,&nbsp;Won Kim ,&nbsp;Dong Han Kim ,&nbsp;Dae Jung Kim","doi":"10.1016/j.jdiacomp.2025.108983","DOIUrl":"10.1016/j.jdiacomp.2025.108983","url":null,"abstract":"<div><h3>Aims</h3><div>To compare the effectiveness of adding a glucagon-like peptide-1 receptor agonist (GLP-1RA) on composite of diabetes-related complications and mortality with that of adding short-acting insulin (SAI) or shifting to premixed insulin among basal insulin (BI)-treated individuals with type 2 diabetes mellitus (T2DM) in South Korea.</div></div><div><h3>Methods</h3><div>From the Health Insurance Review and Assessment Service database, individuals with T2DM who initiated BI treatment and had advanced their treatment regimen from July 1, 2012, to December 31, 2018.</div></div><div><h3>Results</h3><div>A total of 38,634 individuals with T2DM were included in this study. Compared to adding SAI to BI, adding GLP-1RA was associated with decreased risks of cardiovascular complications (hazard ratio 0.56; 95 % confidence interval 0.43–0.72), severe microvascular complications (0.30; 0.19–0.48), diabetes-related hospitalization (0.62; 0.53–0.73), and all-cause mortality (0.27; 0.13–0.57). Compared to switching to premixed insulin, adding GLP-1RA was also associated with lower risk of cardiovascular complications (0.65; 0.51–0.84), severe microvascular complications (0.36; 0.22–0.58), diabetes-related hospitalization (0.62; 0.53–0.73), and all-cause mortality (0.32; 0.15–0.67).</div></div><div><h3>Conclusions</h3><div>In this real-world Korean study, adding GLP-1RA to BI reduced risks of diabetes complications and all-cause mortality than adding SAI or shifting to premixed insulin.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 108983"},"PeriodicalIF":2.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors/SGLT-2i","authors":"Ruoqi Liu ,&nbsp;Zhuomin Qu ,&nbsp;Yizhuo Feng ,&nbsp;Lu Bai ,&nbsp;Xueqian Liu ,&nbsp;Xuemei Fan ,&nbsp;Xiaoqi Liu ,&nbsp;Lingxia Zhao","doi":"10.1016/j.jdiacomp.2025.108981","DOIUrl":"10.1016/j.jdiacomp.2025.108981","url":null,"abstract":"<div><h3>Background</h3><div>Currently, the prevalence of diabetes is rising. Patients with diabetes often face high risks of kidney disease, cardiovascular disease, and retinal disease. Cardiovascular complications are the primary cause of morbidity and mortality in patients with type 2 diabetes mellitus. Finerenone is a novel non-steroidal mineralocorticoid receptor antagonist. Research has shown that finerenone provides renal, cardiac, and retinal protection in patients with type 2 diabetes. Currently, various drugs (angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, sodium-glucose co-transporter 2 inhibitors) are effective in treating diabetic vascular complications, but each has its limitations. Combining finerenone with RAS Inhibitors/SGLT-2i may yield better clinical outcomes.</div></div><div><h3>Methods</h3><div>This review aggregates research on the mechanisms and clinical efficacy of finerenone, RAS Inhibitors, and SGLT-2i used individually, as well as in combination, for the treatment of vascular complications in diabetes from various databases.</div></div><div><h3>Results</h3><div>This review shows that combining finerenone with RAS inhibitors/ SGLT-2 inhibitors can further reduce proteinuria, the urinary albumin-to-creatinine ratio, and the risk of hyperkalemia, slow CKD progression, reduce atherosclerosis, myocardial fibrosis, and hypertrophy, and lower the incidence of atrial fibrillation, myocardial infarction, and heart failure. It can also reduce retinal neovascularization, macular edema, and inflammation. Overall, combining can further lower the risk of complications in type 2 diabetic patients.</div></div><div><h3>Conclusions</h3><div>In summary, combining finerenone with RAS inhibitors and SGLT-2i is a promising treatment strategy. However, the molecular mechanisms and interactions are not fully understood, necessitating more basic research and clinical trials to provide evidence. Combining finerenone with existing treatments may yield better clinical outcomes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108981"},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists","authors":"Wiebke van Beurden ,&nbsp;Yuly P. Mendoza ,&nbsp;Naomi F. Lange ,&nbsp;Jaime Bosch ,&nbsp;Annalisa Berzigotti ,&nbsp;Susana G. Rodrigues","doi":"10.1016/j.jdiacomp.2025.108978","DOIUrl":"10.1016/j.jdiacomp.2025.108978","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Patients with compensated advanced chronic liver disease (cACLD) and treated type 2 diabetes have an increased risk for liver-related events, but data regarding this population is lacking, particularly, taking into account novel treatments. We assessed the role of Fibrosis-4 index and other variables to predict events.</div></div><div><h3>Methods</h3><div>First hepatic decompensation, liver transplantation (OLT), death, hepatocellular carcinoma (HCC) and bacterial infections over a follow-up period of 28.7 (16–49.4) months were retrospectively identified from 106 patients with treated type 2 diabetes and liver stiffness measurement &gt;10 kPa suggesting ACLD. We identified predictors of events using Cox regression. Additionally, we evaluated treatment effect with add-on GLP-1 receptor agonists (GLP-1-RA) compared to other antidiabetic medications.</div></div><div><h3>Results</h3><div>FIB-4 was associated with hepatic decompensation, OLT and death (HR 1.517, 95%CI 1.226–1.879, <em>p</em> ≤ 0.001), HCC (HR 1.369, 95%CI 1.046–1.791, <em>p</em> = 0.022) and bacterial infections (HR 1.379, 95%CI 1.118–1.702, <em>p</em> = 0.003). Propensity score adjusted analysis for GLP-1-RA treatment did not show an effect (HR 0.240, 95%CI 0.044–1.315, <em>p</em> = 0.1). Survival was worse in those with more advanced disease defined by FIB-4 &gt; 2.67 (<em>p</em> = 0.02).</div></div><div><h3>Conclusion</h3><div>FIB-4 is a strong prognostic tool to screen patients and refer them to specialists, in cACLD patients and pharmacologically treated type 2 diabetes, irrespective of treatment.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108978"},"PeriodicalIF":2.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}